Ezetimibe: Efficacy and safety in clinical trials

European Heart Journal, Supplement

Volumn 4, Issue J, 2002, Pages

  Ballantyne, C M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cholesterol lowering drugs; Clinical trials; Ezetimibe; Hyperlipidemia; Low density lipoprotein cholesterol

Indexed keywords

ATORVASTATIN; CIMETIDINE; COLESTYRAMINE; DIGOXIN; ETHINYLESTRADIOL PLUS NORGESTREL; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; WARFARIN;

ARTHRALGIA; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MUSCULOSKELETAL DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; UPPER RESPIRATORY TRACT INFECTION;

EID: 0036895767     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90077-5     Document Type: Review

References (34)

1. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106:1943-8.
2. Salen G, von Bergmann K, Kwiterovich P, et al. Ezetimibe is an effective treatment for homozygous sitosterolemia. Circulation. American Heart Association 2002 Annual Meeting abstract. In press.
3. Knopp RH, Bays H, Manion CV, et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atherosclerosis 2001; 2(suppl): 90. Abstract P 175.
4. Reyderman L, Kosoglou T, Statkevich P, et al. No pharmacokinetic drug interaction between ezetimibe and lovastatin. Clin Pharmacol Ther 2001; 69: P66.
5. Krishna G, Kosoglou T, Ezzet F, et al. Effect of cimetidine on the pharmacokinetcs of ezetimibe. AAPS PharmSci 2001 Annual Meeting Supplement 2001: 3(3). Available from http://www.aapspharmaceutica.com/search/abstract.view.asp?id=304
6. Kosoglou T, Statkevitch P, Bauer KS, et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin. AAPS PharmSci 2001 Annual Meeting Supplement 2001: 3(3). Available from http://www.aapspharmaceutica.com/search/abstract.view.asp?id=290.
7. Statkevich P, Reyderman L, Kosoglou T, et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. Clin Pharmacol Ther 2001; 69(2): P67.
8. Keung A, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives. Poster presented at: American Society of Clinical Pharmacology and Therapeutics; March 6-10, 2001; Orlando, FL, U.S.A.
9. Bauer KS, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin. Poster presented at: American Society of Clinical Pharmacology and Therapeutics; March 6-10, 2001; Orlando, FL, U.S.A.
10. Kosoglou T, Seiberling M, Statkevich, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol 2001; 37(Suppl A): 229A.
11. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54: 309-19.
12. Kosoglou T, Meyer I, Musiol H. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications. Atherosclerosis 2001; 2(suppl): 89.
13. Reyderman L, Kosoglou T, Maxwell S, et al. Lack of pharmacokinetic drug interaction between ezetimibe and fenofibrate. AAPS PharmSci 2001 Annual Meeting Supplement 2001: 3(3). Available from http://www.aapspharmaceutica.com/search/abstract.view.asp?id=366. Abstract.
14. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; in press.
15. Knopp RH, Gitter H, Truitt T, et al. Ezetimibe reduces lowdensity lipoprotein cholesterol: Results of a Phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis 2001; 2(suppl): 38. Abstract W6.2
16. Dujovne C, Held J, Lipka L, et al., for the Ezetimibe Study Group. Does cholesterol and/or fat intake affect plasma lipid efficacy of ezetimibe? J Am Coll Cardiol 2002; 39(suppl A): 227A.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
18. Gagne C, Bays HE, Weiss SR, et al., for the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; in press.
19. Melani L, Lipka L, LeBeaut A, et al., for the Ezetimibe Study Group. Review of the consistency of effect of ezetimibe co-administered with statins in patients with primary hypercholesterolemia with or without hypertriglyceridemia. Diabetes 2002; 51 (suppl 2): A131.
20. Davidson M, McGarry T, Bettis R, Melani L, Lipka L, LeBeaut A, Ramachandran S, Sun S, Veltri E. Ezetimibe co-administered with simvastatin in 688 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 39(suppl A): 226A.
21. Ballantyne C, Houri J, Notarbartolo A, et al., for the Ezetimibe Study Group. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 39(5 suppl A): 227A.
22. Melani L, Mills R, Hassman D, et al., for the Ezetimibe Study Group. Ezetimibe coadministered with pravastatin in 538 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 39(suppl B): 139B.
23. Lipka L, Kerzner B, Corbelli J, et al. Results of ezetimibe co-administered with lovastatin in 548 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 39(9 suppl B): 430B.
24. Lipka L, Melani L, LeBeaut A, Sun S, Suresh R, Veltri E, for the Ezetimibe Study Group. Consistency of LDL-C lowering effect across subgroups of ezetimibe co-administered with statins [abstract]. Eur Hear J 2002: 4(suppl): 19. Abstract 214.
25. Stein E, Stender S, Mata P, et al. Coadministration of ezetimibe plus atorvastatin. Atherosclerosis Supplements 2002; 3: 211-2.
26. Vermaak W, Pinto X, Ponsonnet D, et al. Heterozygous familial hypercholesterolemia: Coadministration of ezetimibe plus atorvastatin. Atherosclerosis Supplements 2002; 3(2):230-231.
27. Thompson G. Familial hypercholesterolemia. Lipoproteins Health Dis 1999; 38: 675-92.
28. Mabuchi H, Koizumi J, Shimizu M, et al., for the Hokuriku-FH-LDL-Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998; 15: 1489-95.
29. Gagne C, Gaudet D, Bruckert E, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-75.
30. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 1771-5.
31. Lee M-H, Lu K, Hazard S, Yu H, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nature 2001; 27: 79-83. [Letter]
32. Kosoglou T, Guillaume M, Sun S, et al. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibiter ezetimibe. Atherosclerosis Supplement 2001; 2: 38
33. Kosoglou T, Fruchart JC, Guillaume M, et al. Coadministration of ezetimibe and fenofibrate leads to favorable effects on apo CIII and LDL subfractions. Atherosclerosis Supplement 2001; 2: 89.
34. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.